Archive for August, 2015« Previous Entries
Monday, August 31st, 2015
The US Food and Drug Administration (FDA) has approved a new combination medication to treat type 2 diabetes. The drug is a combination of empagliflozin and metformin hydrochloride and goes by the brand name Synjardy. It is manufactured by Boehringer Ingelheim and Eli Lilly, and is the third medication with empagliflozin to get approval from [...]
Sunday, August 30th, 2015
According to a new study, patients who stopped taking antihypertensive or anti-blood pressure medications did not see a reversal in their cognitive impairment. Low blood pressure has been recently linked to impairment in cognitive function in older patients.
The study was led by Justine Moonen, of the Department of Psychiatry, Leiden University Medical Center, Netherlands. In [...]
Saturday, August 29th, 2015
A new Swedish study has found that human growth hormone (HGH) treatment can lower to risk fracture in female osteoporosis patients after menopause, several years after treatment. HGH was also found to help women maintain their bone density.
The study was led by Emily Krantz, of Södra Älvsborgs Hospital in Sweden, who said, “Our study is [...]
Thursday, August 27th, 2015
The US Food and Drug Administration (FDA) has approved a new drug called flibanserin (brand name Addyi) from Sprout Pharmaceuticals for treating generalized hypoactive sexual desire disorder in women. This is the first approved drug to treat the disorder in women, specifically pre-menopausal women.
However, the approval did come with a black box warning. Janet Woodcock, [...]
Wednesday, August 26th, 2015
According to a recent study, the drug liraglutide (brand name Victoza) may be linked to increased weight loss in overweight type 2 diabetes patients.
The study was led by Melanie Davies, of the Leicester Diabetes Centre at Leicester General Hospital in the UK, who said, “To our knowledge, this is the first study specifically designed to [...]
Tuesday, August 25th, 2015
A new study has found that beta blockers may be linked to a longer survival time among ovarian cancer patients. Beta blockers are a class of medicines generally indicated to treat high blood pressure. This new study, however, indicates that it could be an effective addition to the treatment regimen for ovarian cancer.
The study was [...]
Monday, August 24th, 2015
A new form of a diabetes medication called metformin may change the game for some type 2 diabetes patients. The delayed-release form of the drug targets the gut and limits absorption in the bloodstream.
The study was led by John Buse, the director of the Diabetes Care Center, University of North Carolina. It focused on metformin-DR, [...]
Sunday, August 23rd, 2015
A new review of multiple studies has found that the medication modafinil (brand name Provigil), which is generally meant to treat narcolepsy, could improve concentration and alertness even in non-sleep-deprived patients.
The review’s results show promise, but also raise ethical concerns over the use of the drug for non-medical needs. The review was co-authored by Ruairidh [...]
Saturday, August 22nd, 2015
A phase I trial of a new medication called guadecitabine (SGI-110) shows promise in treating bone marrow disorders (myelodysplastic syndromes) and blood cancer (acute myelogenous leukemia).
The researchers associated with the trial noted that a currently unpublished phase II trial has already been completed with more promising results, and the phase III trial is now underway.
Friday, August 21st, 2015
According to a new study, young breast cancer patients may be turning down tamoxifen, an important treatment drug, due to concerns that it may affect their fertility.
The study was led by Jacqueline Jeruss, a professor of obstetrics and gynecology-fertility preservation at Northwestern University Feinberg School of Medicine. She said, “Despite the importance of fertility to [...]